NASDAQ · NVO
Healthcare · Drug Manufacturers - General
$42.18
Up+$1.99 (+4.95%)
Updated Nov 5, 2026, 5:45 AM
SID Score
6.3/10
Composite research score
Smart Money
53/100
Neutral
Price performance · NVO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
NVO closed at $42.18 after 21 trading sessions, up 10.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $42.45 | $43.24 | $42.12 | $42.18 | 26.04M |
| Nov 3, 2026 | $40.34 | $40.6343 | $39.96 | $40.19 | 12.22M |
| Nov 2, 2026 | $40.10 | $40.78 | $40.06 | $40.45 | 11.18M |
| Oct 30, 2026 | $39.61 | $40.10 | $39.54 | $40.00 | 15.28M |
| Oct 29, 2026 | $38.67 | $39.22 | $38.56 | $39.14 | 10.44M |
| Oct 28, 2026 | $38.11 | $38.54 | $37.96 | $38.29 | 11.36M |
| Oct 27, 2026 | $38.58 | $39.025 | $38.54 | $38.67 | 6.78M |
| Oct 26, 2026 | $39.02 | $39.235 | $38.67 | $39.13 | 8.04M |
| Oct 23, 2026 | $39.21 | $39.29 | $38.75 | $39.05 | 9.19M |
| Oct 22, 2026 | $39.39 | $39.765 | $39.24 | $39.43 | 8.56M |
| Oct 21, 2026 | $39.25 | $39.49 | $39.05 | $39.06 | 6.8M |
| Oct 20, 2026 | $38.915 | $39.3788 | $38.81 | $39.35 | 9.41M |
| Oct 19, 2026 | $38.65 | $38.84 | $38.35 | $38.42 | 7.45M |
| Oct 16, 2026 | $39.33 | $39.40 | $38.67 | $38.83 | 10.82M |
| Oct 15, 2026 | $38.99 | $39.6787 | $38.89 | $39.22 | 14.78M |
| Oct 14, 2026 | $37.905 | $38.42 | $37.90 | $38.12 | 9.36M |
| Oct 13, 2026 | $38.74 | $38.89 | $37.98 | $38.06 | 9.26M |
| Oct 12, 2026 | $38.85 | $38.85 | $38.26 | $38.58 | 8.72M |
| Oct 9, 2026 | $38.11 | $38.68 | $38.06 | $38.64 | 9.65M |
| Oct 8, 2026 | $37.80 | $38.23 | $37.505 | $38.18 | 11.82M |
| Oct 7, 2026 | $37.57 | $38.47 | $37.508 | $38.26 | 13.67M |
The latest Smart Investors Daily articles mentioning NVO.
Company
Market Activity
Research & News
NVO research
Company profile and research snapshot.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Hold | — |
| Sep 22, 2026 | BANCO SANTANDER | Outperform | — |
| Sep 22, 2026 | DNB CARNEGIE | Buy | — |
| Sep 22, 2026 | TD COWEN | Hold | — |
No generated briefing is available yet.
Yahoo · Nov 4, 2026
The Wegovy maker raised its outlook again and the stock jumped. But its CEO refused to forecast next year, and handed investors six clues instead.
Yahoo · Nov 4, 2026
Novo stock popped early Wednesday on better-than-expected third-quarter sales and profit thanks to resounding beats from its GLP-1 drugs.
Yahoo · Nov 4, 2026
Novo Nordisk reported third quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million, raised its full year sales and profit outlook, and cited strong demand for GLP 1 obesity and diabetes treatments, especially the Wegovy pill. The earnings update showed oral Wegovy rapidly becoming a central product, with management leaning on this momentum while also planning meaningful US list price cuts for Wegovy and Ozempic from January 2027. We will now look at how Novo Nordisk's...
Yahoo · Nov 4, 2026
Novo Nordisk AS (NVO) returned to growth with adjusted sales up 4% and operating profit up 27%, prompting an upward revision of its full-year 2026 outlook.
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S shares closed at $40.19, reflecting a strong one-month rebound of 8.39% per SID market data. However, the stock remains under pressure over longer horizons, declining 8.65% over three months and 19.16% over the trailing twelve months. NVO currently trades below both its 50-day moving average of $41.11 and its 200-day moving average of $44.11, indicating that the recent recovery has not yet reversed the broader downtrend. The 14-day relative strength index stands at 67.0, approaching overbought territory but still within a neutral-to-bullish range. Average daily trading volume is approximately 16.7 million shares, according to Massive/Polygon data. The stock's beta of 0.352 underscores its low correlation with broader market movements, consistent with its positioning as a defensive healthcare name. The current market capitalization stands at approximately $223.5 billion.
Novo Nordisk trades at a price-to-earnings ratio of 12.76, according to SID market data, which represents a notable discount relative to many large-cap healthcare peers that frequently command multiples above 20. The PEG ratio stands at 2.05, suggesting the stock is not inexpensive when adjusting for its expected earnings growth rate. Per SEC filings and derived financial metrics, the price-to-book ratio is elevated at 8.43, reflecting the asset-light, high-return-on-equity business model characteristic of major pharmaceutical companies. The company offers a dividend yield of approximately 3.66%, providing meaningful income for shareholders and ranking among the higher yields in the large-cap healthcare sector. The combination of a compressed P/E multiple alongside a relatively high price-to-book ratio indicates the market is pricing in robust profitability but has moderated its growth expectations compared to prior-year valuations when shares traded significantly higher.
Novo Nordisk's composite smart money score stands at 52 out of 100, generating a neutral signal per SID market data. Institutional positioning represents the strongest component at 23.0 out of 25, indicating that large fund managers maintain substantial and consistent exposure to the stock. Insider activity scores 12.5 out of 25, reflecting a moderate level of transactions from company executives and directors as reported in SEC Form 4 filings. Dark pool activity registers at just 6.5 out of 25, suggesting relatively limited off-exchange accumulation by institutional block traders in recent periods. Congressional trading activity scores 10.4 out of 25, per 13F institutional filings and public disclosure records, showing modest interest from lawmakers' portfolios. The divergence between high institutional conviction and subdued dark pool activity suggests that while large funds remain committed holders, there is limited evidence of aggressive new positioning by sophisticated market participants at current price levels.
Novo Nordisk reported its most recent quarterly earnings of $0.89 per share, exceeding the consensus estimate of $0.81 by $0.08, representing a positive surprise of approximately 9.9% according to company earnings reports. Analyst estimates for the three upcoming quarters are uniformly set at $0.81 per share, reflecting steady expectations for the company's near-term profitability trajectory. The next earnings report is anticipated on August 21, 2026, per analyst estimates, followed by reports on August 25 and August 28. The consistency of the $0.81 estimate across all three forward quarters suggests analysts are modeling stable sequential performance without meaningful acceleration or deterioration. The most recent beat demonstrates Novo Nordisk's capacity to outperform expectations, driven by its dominant GLP-1 receptor agonist franchise. Investors will monitor whether subsequent quarters can similarly exceed the current consensus baseline.
Recent Wall Street analyst coverage of Novo Nordisk reflects a balanced but constructive outlook, per SID consensus data. On September 23, 2026, Rothschild & Co Redburn reiterated a Buy rating, while Jyske Bank maintained its Hold stance on the same date. On September 22, 2026, three firms issued coverage: Banco Santander reiterated an Outperform rating, DNB Carnegie maintained its Buy recommendation, and TD Cowen held its neutral Hold position. Across these five most recent actions, three represent bullish ratings (Buy or Outperform) and two reflect neutral Hold positions, according to Wall Street analyst reports. Notably, all five ratings were reiterations of prior positions rather than upgrades or downgrades, indicating that the recent 8.39% monthly price recovery has not prompted analysts to materially revise their fundamental views. The absence of any Sell or Underperform ratings among recent coverage suggests a consensus floor of support for the stock at current valuation levels.
The latest Smart Investors Daily articles mentioning NVO.
